Lung cancer patients get a second shot: CyberKnife boost after chemoradiation
NCT ID NCT06627738
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can help keep locally advanced non-small cell lung cancer from progressing. About 42 patients who cannot have surgery will receive the boost. The main goal is to see how many are still cancer-free or alive after two years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CyberKnife radiation boost
- What this could lead to
- If successful, this approach could improve the chance of keeping lung cancer from growing back for at least two years after standard chemoradiation.
- What could go wrong
- This is a small, early-phase trial with only 42 participants and no comparison group, so results may not apply broadly. The extra radiation also carries risks like lung inflammation or damage to nearby organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 42 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Feb 2034
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 18 years old or more 2. ECOG 0 to 2 3. Histologically proven non-small cell lung cancer 4. Stage III non-metastatic tumor, not allowing for immediate surgery 5. Volume(s) on the evaluation chest CT scan done at the end of conventional radiotherapy (between 34 \& 46 Gy) meeting the following criteria: * 1 to 3 target volumes of less than 5 cm in greatest diameter * And allowing for the delivery of a CyberKnife boost to be carried out in compliance with the manufacturer requirements and with the doses delivered to the organs at risk (OAR/fractions) defined in appendix 2 6. Patients who have received a " Taxcis " treatment consisting in 2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet) 7. No contraindication to implantable venous devices (IVDs) 8. Patient who has read the patient information note and signed the consent form 9. If applicable, negative pregnancy test\* 10. Eligible for National Health Insurance in France 11. Chest CT scan performed prior to Taxcis Exclusion Criteria: 1. Positive EGFR mutation 2. Exercise-induced dyspnea associated with heart failure equal to or greater than stage III of the New York Heart Association (NYHA) classification, (appendix 3) 3. Coronary syndrome or heart failure in the last three months 4. Pulmonary function test contraindicating radiotherapy: PFT-FEV1 inferior to 1 L. 5. After radio-chemotherapy, presence of any toxicity contraindicating Cyberknife irradiation 6. Vulnerable populations and participants as defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017: * Incapacitated participants who have not given or refused informed consent prior to the onset of their incapacity, who are not under the provisions of article 64 ; * Pregnant or breast-feeding women who are not covered by the provisions of article 66 ; * Adults under legal protection or unable to express their consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Antoine Lacassagne
RECRUITINGNice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut microbes may hold key to why cancer immunotherapy works for some
- Why lung cancer patients lose weight: scientists measure the Body's fuel switch
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Can a targeted pill be safely used for RET-Driven cancers in india?
- New drug combo takes aim at a Hard-to-Treat lung cancer mutation
- Can an Antibody-Drug conjugate crack resistant EGFR lung cancer?